Therapies for Cancer Using RLIP76

Abstract

The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region.

What is claimed is: 
     
         1 . A method of screening for compounds that inhibit RLIP76 activity comprising contacting RLIP76 or a cell expressing RLIP76 with a compound to be tested and determining whether the compound inhibits the activity of RLIP76. 
     
     
         2 . The method of  claim 1 , wherein contacting comprises contacting the compound to be tested with a sequence selected from the group consisting of SEQ ID NO:3-19 or SEQ ID NO:21. 
     
     
         3 . The method of  claim 1 , wherein the RLIP76 comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:22 or SEQ ID NO:23. 
     
     
         4 . The method of  claim 1 , wherein the determining comprises determining GSH conjugate activity. 
     
     
         5 . The method of  claim 1 , wherein the determining comprises determining the transport activity of RLIP76. 
     
     
         6 . The method of  claim 2 , wherein the transport of 4HNE is measured.